Gastroendonews: Tea Leaves No More: Biologics Head-to-Head Produces a Winner
In the first head-to-head trial of biologic treatments for inflammatory bowel disease, vedolizumab (Entyvio, Takeda) was nearly 50% more effective than adalimumab (Humira, AbbVie) in inducing clinical and mucosal remission in patients with moderate to severe ulcerative colitis…
They enrolled 771 patients with moderate to severe ulcerative colitis in the VARSITY study and randomly assigned them to receive 52 weeks of treatment with either vedolizumab or adalimumab…
They had failed other conventional therapies, including 25% in each group that had received an anti–tumor necrosis factor (TNF) agent…
- 31.3% of vedolizumab recipients and 22.5% of those taking adalimumab were in clinical remission after 52 weeks (P=0.0061). Clinical remission was defined as a complete Mayo score of 2 or lower and no subscore greater than 1
- Nearly 40% of patients who received vedolizumab achieved mucosal healing at 52 weeks, compared with 27.7% of adalimumab recipients (P=0.0005).
My take: This study provides a rationale for vedolizumab to be used as a first-line biologic agent for ulcerative colitis.
- Vedolizumab vs. Adalimumab for Infliximab Failure in Ulcerative Colitis: Which is better?
- Getting the Most Out of Vedolizumab
Pingback: Vedolizumab versus Adalimumab for Ulcerative Colitis (part 2) | gutsandgrowth
Pingback: Real-World Vedolizumab: Better Than Expected | gutsandgrowth
Pingback: Comparative Efficacy: Vedolizumab vs Anti-TNF Agents | gutsandgrowth
Pingback: IBD Briefs -October 2020 | gutsandgrowth
Pingback: Vedolizumab Exposure in Newborns | gutsandgrowth